Blog

Publication highlights March 2025

Publication highlights May 2025

Olink proteomics FAQ: Platform, applications & comparisons

Get clear answers to the Olink proteomics platform, including applications, sample types, study scale, data quality, and comparisons with other approaches.

Expanding liquid biopsy with proteomics

This blog highlights how circulating proteins are expanding the capabilities of liquid biopsy beyond tumour-derived DNA.

Recent proteomic advances in neurology

Publication highlights July 2026

The Proteomics of Disease Risk in the UK Biobank

Proteomics-driven insights for pharmaceutical development

Publication highlights April 2026

From Discovery to Clinical Translation: Key Takeaways from the CSF Society and Clinical Neurochemistry Conference

Established and emerging immune signatures in paediatric inflammatory disease: Insights from plasma proteomics

Advancing Precision Psychiatry: Insights from the Neuropsychiatry Congress

AD/PD 2026: Blood-based biomarkers at the core of neurodegeneration research

Proteomic-based approaches to complex neuroimmunology: A window into mechanistic insight

The biological onset of multiple sclerosis (MS) remains poorly defined. A recent Nature Medicine study by Abdelhak et al. used high-throughput discovery proteomics with Olink Explore HT to analyze serum from presymptomatic individuals who later developed MS alongside matched healthy controls. The goal: to define the earliest biological changes preceding neurological symptoms and better understand disease mechanisms.

Publication highlights November 2025

Recent breakthroughs using the scalable, high-multiplex platform Olink Explore HT

Expanding access to high-quality NGS-based proteomics

Olink® Reveal data is now verified for readout on MGI T1+ and G400 sequencers, demonstrating consistent performance with Illumina systems and expanding access to high-quality, NGS-based proteomics.

A bioinformatic resource for pan-cancer proteomics

Explore protein-level variability at population scale

Publication highlights September 2025

Also celebrating 3,000 peer-reviewed articles citing the use of Olink technology!

Precision Medicine Needs Proteomics to Deliver on Its Promise

In his keynote at Olink Proteomics World 2024, Dr. Chris Whelan—founder of the UK Biobank Pharma Proteomics Project—makes a compelling case for why proteomics is essential to fulfilling the promise of precision medicine.

Celebrating 2000 publications citing Olink

Publication highlights April 2025